

Detection of Antibodies against Japanese Encephalitis Virus in Raccoons, Raccoon Dogs and Wild Boars in Japan

Yoshito OHNO¹⁾, Hiroshi SATO²⁾, Kazuo SUZUKI³⁾, Mayumi YOKOYAMA⁴⁾, Shigehiko UNI⁵⁾, Takahiro SHIBASAKI⁶⁾, Mariko SASHIKA⁷⁾, Hisashi INOKUMA⁷⁾, Kazushige KAI¹⁾ and Ken MAEDA¹⁾*

¹⁾Laboratories of Veterinary Microbiology and ²⁾Veterinary Parasitology, Faculty of Agriculture, Yamaguchi University, 1677-1 Yoshida, Yamaguchi 753-8515, ³⁾Hikiwa Park Center, 1629 Inari-cho, Tanabe 646-0051, ⁴⁾Wildlife Management Research Center, Hyogo, 940 Sawano, Aogaki-cho, Tanba 669-3842, ⁵⁾Department of Parasitology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, ⁶⁾Department of Animal Welfare and Livestock, Osaka Prefectural Government, 2-1-7 Ootemae, Chuo-ku, Osaka 540-8570 and ⁷⁾Department of Clinical Veterinary Science, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro City, Hokkaido 080-8555, Japan

(Received 14 January 2009/Accepted 18 March 2009)

ABSTRACT. Japanese encephalitis virus (JEV) infects numerous animal species including humans, horses and pigs. In this study, antibodies against JEV in feral raccoons (*Procyon lotor*), wild boars (*Sus scrofa*) and raccoon dogs (*Nyctereutes procyonoides*) in Japan were examined. The results showed that 40.7% (22 out of 54), 64.5% (40 out of 62), 69.1% (47 out of 68) and 0% (0 out of 20) of raccoons in Hyogo, Osaka, Wakayama and Hokkaido, respectively, had virus-neutralizing antibodies against JEV. In addition, 83.3% (30 out of 36) of wild boars and 63.2% (12 out of 19) of raccoon dogs in Wakayama were seropositive for JEV. There were no significant differences in seroprevalence of JEV between males and females or between adults and juveniles in these wild animals. JEV seroprevalence was compared between 37 raccoons and 30 wild boars captured in a limited period (November 2007 to February 2008), and we found that wild boars (86.7%) were significantly more seropositive for JEV antibody than raccoons (59.5%). In conclusion, JEV was prevalent in wild mammals, indicating that the possibility of JEV infection in humans may still be high in Japan. In addition, these wild animals may be good sentinels to estimate JEV infection risk in residents, as they live near humans and are not vaccinated.

KEY WORDS: Japanese encephalitis virus, raccoon, raccoon dog, wild boar.

J. Vet. Med. Sci. 71(8): 1035-1039, 2009

Japanese encephalitis virus (JEV), which is mainly transmitted to humans by *Culex tritaeniorhynchus*, is responsible for an acute infection of the central nervous system that can result in encephalitis. Approximately 50,000 cases of JEV infection and 10,000 deaths, mostly among children and the elderly, are reported every year in the Southeast Asian and western Pacific regions. Japanese encephalitis (JE) used to be a major public health concern in Japan. More than 100 cases of JE were reported annually in the 1960s. However, the number of cases has decreased markedly, and fewer than 10 cases have been reported annually since the 1990s. This is apparently due to changes in agricultural and animal husbandry practices, as well as a successful program of JEV vaccination.

Nonetheless, serosurveys of JEV in pigs show almost 100% positivity for JEV every year in western Japan [5]. It has been reported that JEV RNA was present in cerebrospinal fluid samples from 4 of 57 aseptic meningitis human cases from 1999 to 2002 in Hiroshima [7] and that a half-bred horse kept in Tottori died after JEV infection in August 2003 [18]. Although JEV has been circulating in Japan and many people are at risk of exposure, mouse brain-grown, formalin-inactivated JE vaccination was ceased in May 2006, primarily because of side effects. Whether JE vacci-

nation is necessary in Japan is now being discussed.

JEV-infected mosquitoes bite a variety of animals, including humans, horses, and pigs. Infection of humans and horses sometimes causes lethal disease, but infection of other animals is thought to be almost subclinical or benign. Pigs and wild birds are considered to be amplifiers, as they develop high titers of viremia, which provides an excellent source of infection for mosquitoes. In Japan, pigs are examined each summer as sentinel for sero-surveys of JEV (May to October) [6].

Raccoons (*Procyon lotor*) and wild boars (*Sus scrofa*) are widely distributed throughout Japan. In recent years, the number of raccoons has increased, and their distribution has expanded. In addition, wild boars have been observed foraging through garbage in urban areas. These animals might therefore affect the lifecycle of infectious diseases in Japan. In raccoons in the North America, it has been reported that more than 75.0% in Los Angeles [1] and 19.2% (15 out of 78) in southern Wisconsin [2] have virus-neutralizing (VN) antibodies against West Nile virus (WNV). In Singapore, VN antibodies against JEV were detected in all 28 wild boars tested from June to July 1999 [13]. In the Northern areas of Okinawa Island and Iriomote Island, 64.6% (64 out of 99) and 3.7% (1 out of 27) of Ryukyu wild boars (*Sus scrofa riukiuanus*), respectively, were seropositive for JEV antibody in the period of 1997 to 2005 [9]. Moreover, JEV RNA was detected in a Ryukyu wild boar (2%; 1 out of 50) caught on Okinawa Island in May 1998 [10]. In Hiroshima,

* CORRESPONDENCE TO: MAEDA, K., Laboratory of Veterinary Microbiology, Faculty of Agriculture, Yamaguchi University, 1677-1 Yoshida, Yamaguchi 753-8515, Japan.
e-mail: kmaeda@yamaguchi-u.ac.jp

68.0% of wild boars captured around residential areas from November 2004 to February 2005 had VN antibodies against JEV [4]. In this region, 4 JEV cases in humans have occurred, but local pig farms are isolated from residential areas. Therefore, it has been speculated that wild boars may be acting as amplifiers for transmission of JEV to humans, as wild boars are closely related to the domestic pig. In humans and horses in Japan, it is difficult to serologically detect JEV infection because most individuals are inoculated with inactivated JE vaccine. Therefore, raccoons and wild boars, which are not inoculated with JE vaccine, are thought to be good sentinels for JEV infection in humans.

In this study, antibodies against JEV in wild animals were examined in order to clarify the JEV infection risk in humans in Japan.

MATERIALS AND METHODS

Cells and viruses: Vero 9013 cells (JCRB number; JCRB9013) originating from an African green monkey were purchased from Human Science Research Resource Bank (HSRRB, Japan), and were cultured in Eagle's minimum essential medium (EMEM; GIBCO, U.S.A.) with 5% heat-inactivated fetal calf serum (FCS; CELlect, MP Biomedicals, U.S.A.), 1 mM sodium pyruvate, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in 5% CO₂. JEV/sw/Chiba/88/2002, which was kindly provided by Dr. Tomohiko Takasaki (National Institute of Infectious Diseases, Japan), was isolated from peripheral blood mononuclear cells of a healthy pig in 2002, and was genetically classified into genotype I [9]. JEV was propagated in C6/36 cells purchased from HSRRB (JCRB number; IFO50010) in EMEM with 10% FCS at 28°C and stored at -80°C until use.

Serum samples: A total of 204 raccoon serum samples were analyzed. Of these, 54 were collected in Hyogo from May 2005 to June 2006, 62 were collected in Osaka from June 2006 to February 2007, 68 were collected in Wakayama from June 2007 to January 2008 and 20 were collected in Hokkaido from May to September 2007. In addition, sera were collected from 36 wild boars in Wakayama from November 2007 to February 2008, and 19 samples were collected from raccoon dogs in Wakayama from November 2007 to March 2008. All sera were inactivated by incubation at 56°C for 30 min and then kept at -20°C until use.

Plaque assay for titration of viruses: Viral infectivity was measured by plaque formation assay. Serially diluted viruses were inoculated onto Vero 9013 cells in a 6-well plate (Sumitomo Bakelite, Japan). After incubation for 90 min at 37°C in 5% CO₂, the cells were washed twice with EMEM and overlaid with 0.8% agarose (SeaPlaque agarose, FMC BioProducts, U.S.A.) in EMEM containing 5% FCS. The plates were then incubated at 37°C in 5% CO₂ for 4 days. The cells were fixed with 5% buffered formaldehyde for 1 hr, and the agarose layers were removed. After staining with crystal violet, plaques were counted.

Virus-neutralizing (VN) test: In order to determine

whether sera contained VN antibody against JEV, a VN test was carried out basically according to a previous report [15]. Briefly, sera were diluted to 1:5 in EMEM containing 2% FCS. The diluted sera or medium alone (control) were mixed with equal volumes of virus solution containing 100 PFU and were then incubated at 37°C for 90 min. After incubation, the mixtures were added to Vero 9013 cells, and a plaque assay was carried out as described previously. Sera that reduced the number of plaques by more than 80% in comparison with the mean number of plaques in control wells were considered to be positive according to a previous report of WNV seroprevalence in wild mammals [3].

Next, in order to determine the VN titer of JEV-positive sera, sera were diluted to 1:10 and then serially two-fold diluted from 1:20 to 1:640. The diluted sera were mixed with equal volumes of virus solution containing 100 PFU and then incubated at 37°C for 90 min. The mixtures were added to Vero 9013 cells, and a plaque assay was carried out. The titer of VN antibody was expressed as the highest dilution of serum that reduced the number of plaques by more than 80% in comparison with control wells without serum [3].

Statistical analysis: To analyze the results statistically, chi-square and Fisher's exact probability tests were performed. The significance level was $P < 0.05$.

RESULTS

JEV infection in raccoons: The seroprevalence of JEV in 204 raccoons from 4 regions was examined by VN test. The results showed that 109 (53.4%) had VN antibodies against JEV (Table 1). Although 22 (40.7%) of the 54 raccoons in Hyogo, 40 (64.5%) of the 62 raccoons in Osaka, and 47 (69.1%) of the 68 raccoons in Wakayama were seropositive, none of the 20 raccoons from Hokkaido were seropositive (Fig. 1). Raccoons in Hyogo were significantly less positive for JEV infection than those in Osaka and Wakayama ($p < 0.05$). In addition, 34.4% of males and 50.0% of females in Hyogo, Osaka and Wakayama were seropositive for JEV infection, but there were no significant differences between the sexes. Raccoons are generally thought to be adults when their body weights are over approximately 4.0 kg and are thought to be juveniles when their weights are below 4.0 kg. Based on these weights, there were no significant differences between adults (37.1%) and juveniles (47.4%).

In Wakayama, 2 serum samples were taken from juvenile

Table 1. Seroprevalence of JEV in raccoons, wild boars and raccoon dogs

Place	Raccoon	Wild boar	Raccoon dog
Wakayama	69.1% (47/68)	83.3% (30/36)	63.2% (12/19)
Osaka	64.5% (40/62)	— ^{a)}	—
Hyogo	40.7% (22/54)	—	—
Hokkaido	0% (0/20)	—	—
Total	53.4% (109/204)	83.3% (30/36)	63.2% (12/19)

a) Data not available.




Fig. 1. Locations of Hokkaido, Hyogo, Osaka and Wakayama.

raccoons captured on the same day and at the same site. These juveniles, whose body weights were 2.05 and 2.3 kg, had high VN titers of 1:2560 and 1:5120, respectively. In Hyogo, serum samples from 2 juveniles, whose body weights were 0.95 and 0.90 kg, showed VN titers (1:1280 and 1:1280) higher than those of other sera (Table 2).

JEV infection in wild boars: The seroprevalence of JEV in 36 wild boars in Wakayama was investigated. The results indicated that 30 (83.3%) had VN antibodies against JEV (Table 1). There were no significant differences between males (87.0%) and females (76.9%). Wild boars are generally thought to be adults when their weights are over approximately 50 kg and are thought to be juveniles when their weights are less than 50 kg. Based on these weights, there were no significant differences in JEV infection between adults (90.9%) and juveniles (80.0%). Furthermore, JEV seroprevalence was compared between 37 raccoons and 30 wild boars captured from November 2007 to February 2008. Wild boars (86.7%; 26 out of 30) were significantly more seropositive than raccoons (59.5%; 22 out of 37; Fig. 2).

JEV infection in raccoon dogs: Nineteen raccoon dogs were examined for JEV infection. The results showed that 12 (63.2%) had VN antibodies against JEV (Table 1). No significant differences in JEV infection were observed between males (61.5%) and females (66.7%).

DISCUSSION

In this study, a seroepidemiologic survey of wild animals in the Kinki district was conducted. We found that 40.7%, 64.5% and 69.1% of raccoons in Hyogo, Osaka and Wakayama, respectively, possessed VN antibodies against JEV. On the other hand, raccoons in Hokkaido did not have VN antibodies against JEV. In Hokkaido, cases of JEV infection occur infrequently [14], and a serosurvey of pigs in 2007 also showed that JEV has not spread in Hokkaido [6]. Therefore, the data obtained for raccoons in Hokkaido indicated that our VN test is specific for JEV, and the high seroprevalence of JEV in wild animals suggests that JEV-infected mosquitoes remain in the Kinki region.

The survey of JEV infection in wild boars was conducted in Hiroshima from November 2004 to February 2005 and confirmed that 17 (68.0%) of the 25 tested wild boars were seropositive [4]. As wild boars are closely related to the domestic pig, they are thought to play a similar role as an amplifier for JEV. In Wakayama, 30 (83.3%) of the 36 tested wild boars were seropositive (Table 1), and wild boars (86.7%) were significantly more seropositive than raccoons (59.5%) in the same season (November 2007 to February 2008) (Fig. 2). Wild boars may thus play an important role in the recent infection cycle of JEV. Further studies are required in order to assess their ability to act as an amplifier for JEV.

In Wakayama, 12 (63.2%) of the 19 raccoon dogs had VN antibodies against JEV (Table 1). This is very similar to the results for raccoons (69.1%) in Wakayama, indicating that many species of wild animals in Wakayama may be infected with JEV. The diseases induced in these animals by JEV are unknown, but JEV infection in these animals indicates that JEV has been highly prevalent in the area.

Because of improvements in agricultural methods, decreases in the number of mosquito vectors, isolation of pig farms from urban areas and vaccination programs, there are fewer than 10 cases of JE in Japan each year. However, our data, as well as data from JEV surveillance in pigs [6], indicated that JEV remains epidemic. As wild boars may become viremic for JEV, as in domestic pigs, they may be an important source of JEV in these areas. In addition, there were few raccoons in Japan before 2000, but they now represent one of the major mammals in some areas. In North

Table 2. Virus-neutralizing titer to JEV in raccoons, wild boars and raccoon dogs

Species	Place	Virus-neutralizing titer against JEV										Total	
		<1:10	1:10	1:20	1:40	1:80	1:160	1:320	1:640	1:1280	1:2560		1:5120
Raccoon	Hyogo	32	6	4	3	2	3	1	0	2	1	0	54
	Osaka	22	13	10	6	4	4	3	0	0	0	0	62
	Wakayama	21	10	13	4	7	3	3	1	1	3	2	68
	Hokkaido	20	0	0	0	0	0	0	0	0	0	0	20
Wild boar	Wakayama	6	8	5	6	1	3	1	1	0	0	0	36
Raccoon dog	Wakayama	7	2	5	5	0	0	0	0	0	0	0	19




Fig. 2. Comparison of JEV infection in raccoons and wild boars captured in the same season (November 2007 to January 2008) in Wakayama. The numbers indicate the percentages of JEV-positive animals. Wild boars were significantly more seropositive than raccoons ($p < 0.05$).

America, raccoons have changed the epidemic pattern of rabies and are the most important reservoirs of canine distemper virus. Further study will be required to clarify whether the rapid increase of raccoons in Japan will influence the epidemiological pattern of JEV.

In most mammals, levels of viremia sufficient to infect mosquitoes do not develop. However, in the infection cycle of West Nile virus in the U.S.A., mammals such as the golden hamster (*Mesocricetus auratus*) [17], fox squirrel (*Sciurus niger*) [12], eastern cottontail rabbit (*Sylvilagus floridanus*) [16] and eastern chipmunk (*Tamias striatus*) [11] become sufficiently viremic for mosquito infection. In Wakayama, many wild animals were highly seropositive for JEV. Therefore, it is necessary to define whether some wild animals play a role as amplifiers for transmission of JEV to humans. Further analysis, such as PCR of sera or experimental infection using these wild animals, is needed in order to determine whether such species are amplifiers of JEV.

In conclusion, JEV infects a variety of wild animals living near human residences, indicating that JEV is still endemic in Japan, thus maintaining human infection risks. In addition, wild animals living near human habitats may be good sentinels for zoonoses such as JEV.


ACKNOWLEDGMENTS. The authors would like to thank Dr. Tomohiko Takasaki (National Institute of Infectious Disease) for kindly providing JEV and Dr. Go Abe and Dr. Yohei Matoba (Raccoon Researchers Group) for collecting sera from raccoons. This work was supported by a grant for

Research on Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare of Japan (H20-Shinko-Ippan-003) and by a grant from the Innovation Center of Yamaguchi University.

REFERENCES

- Dietrich, G., Monteneri, J. A., Panella, N. A., Langevin, S., Lasater, S. E., Klenk, K., Kile, J. C. and Komar, N. 2005. Serologic evidence of West Nile virus infection in free-ranging mammals, Slidell, LA, 2002. *Vector Borne Zoonotic Dis.* **5**: 288–292.
- Docherty, D. E., Samuel, M. D., Nolden, C. A., Egstad, K. F. and Griffin, K. M. 2006. West Nile virus antibody prevalence in wild mammals, southern Wisconsin. *Emerg. Infect. Dis.* **12**: 1982–1983.
- Gómez, A., Kilpatrick, A. M., Kramer, L. D., Dupuis, A. P. 2nd, Maffei, J. G., Goetz, S. J., Marra, P. P., Daszak, P. and Aguirre, A. A. 2008. Land use and West Nile virus seroprevalence in wild mammals. *Emerg. Infect. Dis.* **14**: 962–965.
- Hamano, M., Lim, C. K., Takagi, H., Sawada, K., Kuwayama, M., Kishi, N., Kurane, I. and Takasaki, T. 2007. Detection of antibodies to Japanese encephalitis virus in the wild boars in Hiroshima prefecture, Japan. *Epidemiol. Infect.* **135**: 974–977.
- Infectious Diseases Surveillance Center. 2004. Japanese encephalitis. pp. 92–113. *In: National Epidemiological Surveillance of Vaccine-Preventable Diseases.* Tokyo, NIID.
- Infectious Disease Surveillance Center. 2007. Japanese encephalitis (JE) hemagglutinin inhibition (HI) antibody prevalence of domestic pigs in Japan, 2007. http://idsc.nih.go.jp/yosoku/JE/2007JESw/JE07_18.html
- Kuwayama, M., Ito, M., Takao, S., Shimazu, Y., Fukuda, S., Miyazaki, K., Kurane, I. and Takasaki, T. 2005. Japanese encephalitis virus in meningitis patients, Japan. *Emerg. Infect. Dis.* **11**: 471–473.
- Nerome, R., Tajima, S., Takasaki, T., Yoshida, T., Kotaki, A., Chang-Kweng Lim., Ito, M., Sugiyama, A., Yamauchi, A., Yano, T., Kameyama, T., Morishita, I., Kuwayama, M., Ogawa, T., Sahara, K., Ikegaya, A., Kanda, M., Hosoya, Y., Itokazu, K., Onishi, H., Chiya, S., Yoshida, Y., Tabei, Y., Katuki, K., Tabata, K., Harada, S. and Kurane, I. 2007. Molecular epidemiological analyses of Japanese encephalitis virus isolates from swine in Japan from 2002 to 2004. *J. Gen. Virol.* **88**: 2762–2768.
- Nidaira, M., Taira, K., Itokazu, K., Kudaka, J., Nakamura, M., Ohno, A. and Takasaki, T. 2007. Survey of the antibody against Japanese encephalitis virus in Ryukyu wild boars (*Sus scrofa riukiuanus*) in Okinawa, Japan. *Jpn. J. Infect. Dis.* **60**: 309–311.
- Nidaira, M., Taira, K., Itokazu, K., Okano, S., Kudaka, J., Nakamura, M., Ohno, A. and Takasaki, T. 2008. Detection of Japanese encephalitis virus genome in Ryukyu wild boars (*Sus scrofa riukiuanus*) in Okinawa, Japan. *Jpn. J. Infect. Dis.* **61**: 164–165.
- Platt, K. B., Tucker, B. J., Halbur, P. G., Sonthaya Tiawsirirup, Blitvich, B. J., Fabiosa, F. G., Bartholomay, L. C. and Rowley, W. A. 2007. West Nile virus viremia in Eastern Chipmunks (*Tamias striatus*) sufficient for infecting different mosquitoes. *Emerg. Infect. Dis.* **13**: 831–837.
- Root, J. J., Oesterle, P. T., Nemeth, N. M., Klenk, K., Gould, D. H., Mclean, R. G., CLARK, L. and Hall, J. S. 2006. Experimental infection of fox squirrels (*Sciurus niger*) with West Nile

- virus. *Am. J. Trop. Med. Hyg.* **75**: 697–701.
13. See, E., Tan, H. C., Wang, D., Ooi, E. E. and Lee, M. A. 2002. Presence of hemagglutination inhibition and neutralization antibodies to Japanese encephalitis virus in wild pigs on an offshore island in Singapore. *Acta Tropica*. **81**: 233–236.
 14. Takasaki, T., Yabe, S., Nerome, R., Ito, M., Yamada, K. and Kurane, I. 2003. Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. *Vaccine* **21**: 4514–4518.
 15. Takashima, I., Watanabe, T., Ouchi, N. and Hashimoto, N. 1988. Ecological studies of Japanese encephalitis virus in Hokkaido: Interepidemic outbreaks of swine abortion and evidence for the virus to overwinter locally. *Am. J. Trop. Med. Hyg.* **38**: 420–427.
 16. Tiawsirisup, S., Platt, K. B., Tucker, B. J. and Rowley, W. A. 2005. Eastern cottontail rabbits (*Sylvilagus floridanus*) develop West Nile virus viremia sufficient for infecting select mosquito species. *Vector Borne Zoonotic Dis.* **5**: 342–350.
 17. Xiao, S. Y., Guzman, H., Zhang, H., Travassos da Rosa, A. P. and Tesh, R. B. 2001. West Nile virus infection in the golden hamster (*Mesocricetus auratus*): a model for West Nile encephalitis. *Emerg. Infect. Dis.* **7**: 714–724.
 18. Yamanaka, T., Tsujimura, K., Kondo, T., Yasuda, W., Okada, A., Noda, K., Okumura, T. and Matsumura, T. 2006. Isolation and genetic analysis of Japanese encephalitis virus from a diseased horse in Japan. *J. Vet. Med. Sci.* **68**: 293–295.



Natural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program

Eiji Konishi^{a,b,*}, Yoko Kitai^a, Yukiko Tabei^c, Koichi Nishimura^d, Seiya Harada^d

^a Division of Infectious Diseases, Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan

^b Division of Vaccinology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan

^c Division of Virology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan

^d Division of Microbiology, Kumamoto Prefectural Institute of Public Health and Environmental Science, Kumamoto, Japan

ARTICLE INFO

Article history:

Received 20 October 2009

Received in revised form

19 December 2009

Accepted 6 January 2010

Available online 15 January 2010

Keywords:

Japanese encephalitis

Nonstructural protein

Neutralizing antibodies

Natural infection rate

ABSTRACT

Japanese encephalitis (JE) is a serious disease in Asia, but it can be prevented by vaccination. To evaluate the necessity for vaccination in areas with reduced numbers of vector mosquitoes, as well as patients, it is critical to understand the frequency of natural virus exposure. An antibody survey was recently conducted to estimate current natural infection rates in Japan, where the vaccination rate has dropped in recent years. Serum samples were collected in 2004–2008 from inhabitants of Kumamoto Prefecture in west Japan, and in 2004–2006 from the Tokyo Metropolitan area of east Japan. Average annual infection rates estimated from the prevalence of antibodies to the nonstructural 1 protein (NS1) of JE virus was 1.8% in Kumamoto and 1.3% in Tokyo. When estimated from percentages of populations with detectable neutralizing antibodies but with no vaccination history, the average annual infection rate was 2.6% in both survey areas. Thus, JE virus remains present and active in nature in Japan. Therefore, continuing a vaccination program is indispensable to prevent JE infection in humans.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Japanese encephalitis (JE) is a major public health issue in Asia [1]. Annually, approximately 50,000 cases occur and 10,000 die from this disease [2], which is caused by the Japanese encephalitis virus (JEV), a member of the genus *Flavivirus* in the family *Flaviviridae* that is transmitted by mosquitoes [3]. In Japan, Korea and Taiwan, it has been demonstrated that this disease can be controlled by human vaccination [4]. A formalin-inactivated, purified JEV preparation has been widely used to protect human populations from JE.

In Japan, the annual number of human JE cases has been reduced from over 1000 before 1967 to less than 10 after 1992 [5]. This followed the initiation in 1967 of the nationwide distribution of a high-purity inactivated JE vaccine. It has been thought that the reduction in JE cases might also have resulted from the decreased number of vector mosquitoes. In conjunction with the relocation of many pig farms to areas removed from residential zones, such factors would have reduced the efficiency of JEV transmission to human populations from amplifier pigs through vector mosquitoes

[6]. Reports on post-vaccination events like acute disseminated encephalomyelitis (ADEM) [7,8] raised opposition to JE vaccination. Then, the occurrence of a case with severe ADEM following JE vaccination prompted the Japanese Government in 2005 to withdraw its strong recommendation for JE vaccination for both 3-dose primary and 2-dose booster immunizations [9,10].

Following the suspension, the JE vaccination rate decreased. The national JE surveillance program indicated that only approximately 10% of children aged 3–4 years were vaccinated with JE vaccine in 2007 [11]. Accordingly, the surveillance program in the same year indicated that only approximately 20% of children of identical ages possessed neutralizing antibodies against JE [12]. Therefore, increasing populations susceptible to JEV infection have raised concerns about the recurrence of JE.

The natural activity of JEV is a critical factor in the debate about the necessity to continue a vaccination program. In Japan, except for the non-endemic northern areas, annual infection rates in humans ranged from 3 to 17% before 1960 [13–16], 5 to 10% in the early 1980s and mid-1990s [17] and 0.2 to 3.4% between 2001 and 2004 [18,19]. Although reports on annual infection rates in humans have not been available since 2004, JEV infection in swine is reported every summer by the national JE surveillance program, particularly in the south and west of Japan [20]. The 2008 surveillance report [21] is shown in Fig. 1.

The present paper reports annual infection rates during 2004–2008 among the inhabitants of Kumamoto Prefecture (west

* Corresponding author at: Department of International Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan. Tel.: +81 78 796 4594; fax: +81 78 796 4594.

E-mail address: ekon@kobe-u.ac.jp (E. Konishi).

Japan) and of the Tokyo Metropolitan area (east Japan) during 2004–2006. Natural infection was detected by measuring antibodies to the nonstructural protein 1 (NS1) of JEV, which allowed the differentiation of infected from vaccinated individuals. Annual infection rates were also obtained from percentages of populations who had no history of JE vaccination but possessed neutralizing antibodies against JEV. Kumamoto and Tokyo are representative of the west and east areas of Japan, since the time-related JEV antibody prevalence in swine in these areas during the epidemic season, as reported from the national JE surveillance program [20,21], are roughly similar to those in their neighboring prefectures.

2. Materials and methods

2.1. Human serum samples

As a part of a national JE surveillance program, sera were collected after signed consent was received from 1190 inhabitants of Kumamoto Prefecture from 2004 through 2008, and 955 inhabitants of the Tokyo Metropolitan area from 2004 through 2006. Upon receiving the consent, inhabitants completed questionnaires including questions about JE vaccination history. For most children, parents were able to refer to a notebook wherein was recorded their child's vaccination history. The period of collecting serum samples was from late August to mid-October in Kumamoto and from July to October in Tokyo. The locations of these survey areas are shown in Fig. 1. Survey subjects ranged in age from 0 to 98 years in the Kumamoto samples and 0 to 76 years in the Tokyo samples. Ages were grouped in 10-year increments, except for those aged over 60 years, which were grouped in one age group (see Supplementary Tables S1 and S2 for age and gender compositions). Serum samples from babies aged <6 months, which may contain maternally transferred antibodies, were not used. All of the Kumamoto samples were examined for both NS1 and neutralizing antibodies, while in the Tokyo samples, a reduced number of samples was used for NS1 antibody testing because of the limited volume of sera remaining (indicated by parenthesis in Supplementary Table S2). The use of all human samples in the present study was approved by the Ethical Committees of the Kobe University School of Medicine and the Tokyo Metropolitan Institute of Public Health.




Fig. 1. Map of Japan indicating geographic locations of Kumamoto Prefecture and the Tokyo Metropolitan area and seropositivity in 2008 of the swine population in each prefecture as reported by the national JE surveillance program [21]. Seropositivity of swine is expressed semi-quantitatively in the figure. Note that the surveillance program was not conducted in some prefectures. The island depicted in the square is Okinawa Prefecture, the southernmost prefecture in Japan. Broken lines indicate latitude expressed in degrees north.

2.2. Swine serum samples

As a part of a national JE surveillance program, sera were obtained from 6-month-old swine at slaughterhouses in Kumamoto Prefecture in 2004–2008. Twenty samples were collected on eight occasions during the JE epidemic season from July to September.

2.3. ELISA for quantifying NS1 antibodies

ELISA was performed as described previously [22]. Briefly, plates sensitized with purified NS1 antigens were blocked with the ELISA diluent and then incubated serially with test sera, alkaline phosphatase-conjugated goat anti-human IgG, and *p*-nitrophenyl phosphate. The NS1 antigens were obtained from culture fluids of 3G8 cells stably transfected with the NS1 and NS2A genes of JEV [23] by immunoaffinity purification with a monoclonal specific for NS1 (JE-2D5). The ELISA diluent was composed of 0.05 M Tris-HCl (pH 8.0) containing 0.2% casein, 0.05% Tween 20, 1 mM EDTA and 0.15 M NaCl [24]. The ELISA diluent was used for preparing dilutions of test sera and the conjugate, as well as for blocking. A non-sensitized control plate was run in parallel, and the absorbance obtained with non-sensitized wells was subtracted from those obtained with antigen-sensitized wells, to eliminate nonspecific reactions. To minimize interplate variations, a constant positive control serum was included in every plate, and absorbances obtained with test samples were adjusted with the value for the positive control as 1.0. The adjusted absorbances were expressed as ELISA values. ELISA values of 0.185 or higher were determined as positive for NS1 antibodies.

2.4. Neutralization test

Neutralizing antibodies contained in human sera were titrated by a standard method as described elsewhere [25], as a part of a national JE surveillance program. In this method, complement was not included in the virus-antibody mixture. The neutralizing antibody titer was expressed as the highest serum dilution yielding a 50% reduction in plaque number. Serum samples showing neutralizing antibody titers of 1:10 or higher were determined to be positive for antibodies to JEV.

2.5. Hemagglutination-inhibition (HAI) test

HAI test was performed by a micro-modification of the method of Clarke and Casals [26], with four hemagglutinin units of the JEV antigen (JaGAr#01 strain; Denka Seiken, Niigata, Japan). Sera showing HAI antibody titers of 1:10 or higher were determined to be positive for JEV antibodies.

2.6. Statistical analysis

Significant differences in antibody prevalence were evaluated by the chi-square test with the Yates' correction factor. Probability levels (*P*) of less than 0.05 were considered significant.

3. Results

3.1. NS1 antibody levels in the Kumamoto populations

Sera collected in Kumamoto Prefecture were examined for NS1 antibodies (Fig. 2A). The overall prevalence of NS1 antibodies in 2004–2008 was 7.6% (90/1190). Males and females did not show significant differences in overall prevalence in each year. However, when comparisons were made among each age group, males showed a higher prevalence than females in the 60s age group in




Fig. 2. NS1 antibody prevalence in Kumamoto populations in 2004–2008. (A) Age-dependent antibody prevalence curve in males (closed circle), females (closed triangle) and total (open square) populations. Asterisk indicates significant differences between males and females ($P < 0.05$). (B) Annual infection rates estimated from NS1 antibody prevalence in males (closed circle), females (closed triangle) and total (open square) populations. Asterisks indicate significant differences between years in the total population: * $P < 0.05$ and ** $P < 0.01$.

2004. Antibody prevalence increased with age: in the total population (2004–2008), the age groups of the 50s or the 60s showed higher prevalences than those of the 0s, 10s or 20s ($P < 0.001$) or the 30s ($P < 0.01$) and; the 40s age group showed a higher prevalence than did the 0s or 10s ($P < 0.01$).

The annual infection rate was calculated by dividing the NS1 antibody prevalence by the duration of NS1 antibodies (4.2 years [22]). The mean annual infection rate obtained in 2004–2008 was 1.9% in males, 1.7% in females and 1.8% in the total population without significant gender differences ($P > 0.05$). The annual infection rates in 2005–2007 were higher than those in 2004 and 2008: significant differences were detected between 2004 and 2007 and between 2008 and each year for 2005–2007 ($P < 0.05$ or $P < 0.01$; Fig. 2B).

3.2. Neutralizing antibody titers in the Kumamoto populations

The prevalence of neutralizing antibodies was obtained using the same populations as used for the NS1 antibody survey (Fig. 3). Although age-dependent prevalence curves varied between males

and females probably based on the small population size in each age group in different years, the total population (2004–2008) showed a tendency that the prevalence increased between the 0s and 10s, decreased between the 20s and 40s and again increased between the 40s and 60s age groups. The overall prevalence for 2008 (55.8%) was lower than those for 2004 (66.4%; $P < 0.05$) and 2005 (70.5%; $P < 0.001$). Antibody prevalences in the 0s age group in 2007–2008 were lower than those in 2004–2006 ($P < 0.05$).

Questionnaires related to the vaccination history of each subject provided a total of 145 children aged 9 years or younger who had not received any JE vaccine (Table 1). Of these, 15 (10.3%) were positive for neutralizing antibodies, indicating natural infection with JEV. Since the average survival period of these subjects was 4.0 years, the annual infection rate was calculated to be 2.6% (Table 1). The annual infection rates in males and females obtained in the same way were 2.4 and 2.9%, respectively.

Prevalence of HAI antibodies among pigs started to increase in late July in 2005 and 2007 and in late August in other years (Fig. 4). The time when the prevalence became over 50% was the latest in 2008 (mid-September). These results suggested that the




Fig. 3. Neutralizing antibodies in Kumamoto populations in 2004–2008. Age-dependent antibody prevalence was obtained in males (closed circle), females (closed triangle) and total (open square) populations. Asterisks indicate significant differences between males and females: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Table 1

Annual infection rates in Kumamoto, 2004–2008, and Tokyo, 2004–2006, calculated from the number of unvaccinated children aged 0–9 years with neutralizing antibodies.

Area	Gender	Total no.	No. of positive	% positive	Average survival period (year) ^a	Annual infection rate (%) ^b
Kumamoto	Male	80	7	8.8	3.7	2.4
	Female	65	8	12.3	4.3	2.9
	Total	145	15	10.3	4.0	2.6
Tokyo	Male	127	13	10.2	3.2	3.2
	Female	73	3	4.1	2.8	1.5
	Total	200	16	8.0	3.1	2.6

^a Calculated from the age of the subjects. The survival period of each subject was supposed to be 0.5 years more than the age: for instance, the survival period of a subject aged 1 year was regarded as 1.5 years.

^b Calculated by dividing the “% positive” by the “average survival period”.

spread of JEV was earlier in 2005 and 2007 than in other years and that JEV activity in 2008 was the lowest for the 2004–2008 period in Kumamoto, as far as the activity could be estimated by swine antibodies.




Fig. 4. Time-related prevalence of HAI antibodies in swine in Kumamoto Prefecture. Sera were collected in early (1), mid (2) and late (3) July, August and September in 2004 (closed circle), 2005 (closed triangle), 2006 (closed square), 2007 (open circle) and 2008 (open triangle).

Finally, we examined the relationship between neutralizing and NS1 antibodies. Overall, 6.4% of the population were positive for both neutralizing and NS1 antibodies, 57.1% were positive only for neutralizing and 1.2% were positive only for NS1 antibodies, while 35.4% were negative for both antibodies. By age-dependent curves (Fig. 5), approximately 80% of the 10s and 20s populations had only neutralizing antibodies. As well, approximately 20% of the 50s and 60s were positive for both neutralizing and NS1 antibodies, in contrast to less than 5% of the 30s or lower age groups.

3.3. NS1 antibody levels in the Tokyo populations

NS1 antibodies in sera collected in the Tokyo Metropolitan area were analyzed in a similar way to that used for the Kumamoto populations (Fig. 6A). Overall prevalence of NS1 antibodies in 2004–2006 was 5.5% (32/578). No significant differences were shown in the prevalence between males and females in each age group in each year ($P > 0.05$). Similar to the Kumamoto populations, prevalence increased with age. Among the total population (2004–2006), the 50s and 60s age groups showed higher prevalences than the 10s ($P < 0.001$) or 20s ($P < 0.01$), while the 50s age group showed a higher prevalence than that the 0s ($P < 0.05$).

The mean annual infection rates calculated from NS1 antibody prevalences in 2004–2006 were 1.0% in males, 1.6% in females and 1.3% in the total population without significant gender differences




Fig. 5. Relationships between neutralizing and NS1 antibodies in Kumamoto populations. Age-dependent percentages were obtained from populations who were positive for both neutralizing and NS1 antibodies (closed circle), positive only for neutralizing antibodies (closed triangle), positive only for NS1 antibodies (open circle), and negative for both antibodies (open triangle).




Fig. 7. Neutralizing antibodies in Tokyo populations in 2004–2006. Age-dependent antibody prevalence was obtained in males (closed circle), females (closed triangle) and total (open square) populations.




Fig. 6. NS1 antibody prevalence in Tokyo populations in 2004–2006. (A) Age-dependent antibody prevalence curve in males (closed circle), females (closed triangle) and total (open square) populations. (B) Annual infection rates estimated from NS1 antibody prevalence in males (closed circle), females (closed triangle) and total (open square) populations. Asterisk indicates a significant difference between years in the male population ($P < 0.05$).

($P > 0.05$). The annual infection rates were not significantly different for the years 2004–2006, except for in the male population where the rate was significantly higher in 2004 than 2006 ($P < 0.05$; Fig. 6B).

3.4. Neutralizing antibody titers in the Tokyo populations

Age-dependent prevalence curves of neutralizing antibodies (Fig. 7) showed a tendency similar to those shown in the Kumamoto populations (Fig. 3): a low prevalence among the 0s years, high prevalences for the 10s and 20s and a low prevalence for the 40s age groups in the total population (2004–2006). The prevalence of neutralizing antibodies was not significantly different between genders in each year and each age group ($P > 0.05$; Fig. 7). On the other hand, the prevalence was significantly lower in 2006 than 2004 in the 0s age group in the male and total populations ($P < 0.05$).

The annual infection rate calculated from the number of children aged 9 years or younger who had not received any doses of JE vaccine was 3.2% in males, 1.5% in females and 2.6% for the total population (Table 1).

4. Discussion

The present survey estimated annual infection rates using two types of antibodies, those to JEV structural or those to nonstructural proteins. Because most people among the total Japanese population have received inactivated JE vaccine in their childhood, identification of naturally infected individuals required a serological method based on antibodies to nonstructural proteins induced only by infection. On the other hand, the recent reduction in vaccination rates allowed us to detect natural infection using a conventional neutralization test. If an unvaccinated individual possessed neutralizing antibodies, we considered that it was as a result of infection. In the present study, the population used for this estimation was limited to those aged 9 years or younger: the information for vaccination history is more reliable in younger than in older people since the objects of the JE vaccination program were

children aged 3–15 years before May of 2005 and 3–10 years after June of 2005.

The annual infection rates obtained based on neutralizing antibodies (2.6% in Kumamoto and Tokyo) were higher than those based on NS1 antibodies (1.8% in Kumamoto and 1.3% in Tokyo). The cutoff value differentiating positive from negative samples in ELISA for measuring NS1 antibodies was determined by the confidence limit calculated from the mean and standard deviation obtained with negative controls at a probability level of 0.1% [22]: thus, theoretical false-positives may arise in only one of a thousand negative samples. On the other hand, the neutralization test was based on a 50% plaque reduction method and the cutoff value was an antibody titer of 1:10, which cannot be considered a stringent cutoff value since a recent clinical trial for evaluating an inactivated JE vaccine used a cutoff of 1:20 for selecting uninfected volunteers [27]. However, in the present study, even if the cutoff was increased to 1:20, the annual infection rate was identical in Kumamoto populations and 2.3% in Tokyo populations. Vaccine-induced “sterile” immunity in which neutralizing antibodies inactivate the virus before infecting the host cells is also a potential reason why the annual infection rates estimated from neutralizing antibodies were higher than those estimated from NS1 antibodies. Although annual infection rates estimated by the two methods varied from 1.3 to 2.6%, this approach provided strong evidence of recent natural JEV activity in Japan.

The national JE surveillance program has reported higher natural JEV activities in Kumamoto Prefecture than in the Tokyo Metropolitan area [20,21], with HAI antibody prevalence among swine during 2004–2008 averaging 59% in Kumamoto and 18% in Tokyo. This is consistent with the difference between the numbers of JE patients reported during the same period in Kumamoto (6 cases) and in Tokyo (0 cases) [28,29]: of particular note was a 3-year-old unvaccinated patient reported in Kumamoto Prefecture in 2006. On the other hand, the difference in NS1 antibody prevalence between Kumamoto in 2004–2008 (7.6%) and Tokyo in 2004–2006 (5.5%) was not statistically significant ($P > 0.05$). Moreover, the annual infection rates estimated from the prevalence of neutralizing antibodies were identical (2.6%). Variations could have occurred in the survey results in both areas, since the survey population was small: 0.012–0.017% and 0.0024–0.0026% of the total population in Kumamoto Prefecture (1,842,140 people) and the Tokyo Metropolitan area (12,570,904 people), respectively, based on the 2005 census. However, the presence of NS1 antibodies and the presence of neutralizing antibodies in unvaccinated children undoubtedly demonstrated natural JEV activities during 2004–2008 in Kumamoto and 2004–2006 in Tokyo. In fact, 2 of the 3 patients in 2008 occurred in east Japan close to Tokyo [29].

In Kumamoto, the annual infection rates estimated from NS1 antibodies were higher in 2005–2007 (2.1–2.7%) than in 2004 (1.3%) or 2008 (0.9%). This appeared consistent with the start of the circulation of JEV in nature, which was earlier in 2005 and 2007 than in other years, as determined by the time course of the prevalence of HAI antibody in swine. However, considering the variation in annual infection rates based on the period for collecting serum samples (from late August to mid-October) and the duration of NS1 antibodies (4.2 years), it cannot always be taken to mean that the human NS1 antibody results correlated with those for swine HAI antibodies.

The age-dependent prevalence of neutralizing antibodies showed similar patterns in Kumamoto and Tokyo. These patterns were consistent with the pattern reported from the national JE surveillance program: that is, an increase between the 0s and 10s, a decrease between the 20s and 40s and then an increase between the 40s and 60s age groups [12]. The low prevalence in the 0s age group reflected a recent decrease in the vaccination rate. The prevalence in this age group was not as high as those reported in 2004

by the national JE surveillance program [28]. During the present survey period, the prevalence in the 0s age group was significantly reduced in both Kumamoto and Tokyo. By contrast, the high percentages in the 10s and 20s age groups are considered as the result of the high vaccination rates before 2004. The low percentage in middle age groups can probably be attributed to the duration of the effect of inactivated JE vaccine and the assumption that almost none received a vaccination after they were 15 years old. The high prevalence rates in the older age groups may be explained by the fact that these ages did not receive vaccinations and were exposed to the JEV antigen initially by natural infection, which may induce stronger memory immune responses than those induced by vaccination.

The relationship between neutralizing and NS1 antibodies varied with age. Since the strategies to measure neutralizing or NS1 antibodies are fundamentally different in terms of the assay method (functional or binding assays, respectively), as well as the type of target protein (structural or nonstructural proteins, respectively), these antibodies do not always appear to correlate. Specifically, an individual who was vaccinated but not infected may develop only neutralizing but not NS1 antibodies. That a high percentage (57.1%) of the population is positive only for neutralizing antibodies (Fig. 5) seems to be attributable to the vaccination. The fact that the populations positive for both neutralizing and NS1 antibodies were higher among the 50s and 60s than in other age groups is related to the present age-dependent curves of NS1 and neutralizing antibodies; with higher prevalences shown in both populations. The high prevalence of NS1 antibodies in the 50s and 60s age groups in Kumamoto and Tokyo populations may be related to differences in the first exposure to a JEV antigen (infection or vaccination) and/or simply how many times an individual has acquired natural infections.

A question arises why the numbers of reported JE patients have stayed low in situations where a relatively large number of unvaccinated children have been exposed to natural JEV infection. One possible explanation is the attenuation of JEV currently circulating in Japan. It is speculated that the attenuation may relate to the recent genotype shift from type 3 to 1 [30] and/or the deletion of about 10 nucleotides in the 3'-untranslated region in recent isolates [31]. Attenuation of JEV is considered to decrease the clinical:subclinical infection rate, resulting in high antibody prevalence with few patients. In recent years, JEV sequences have been detected by polymerase chain reaction in cerebrospinal fluid samples from children with aseptic meningitis in Japan [32]. Attenuation may have caused a shift in the major clinical manifestation caused by JEV infection from encephalitis to meningitis, which would have contributed to the reduction in the numbers of reported JE patients.

In conclusion, the present survey, conducted in areas of west and east Japan, revealed continuous JEV activities in nature and recent exposures of human populations to JEV infection. This indicates that the JEV transmission route to humans still exists in domestic and peridomestic environments in Japan. Although the wild JEV strain might be currently attenuated, it is possible that the virus could recover virulence through natural mutation and foreign pathogenic JEV strains could invade Japan [33]. These results highlight the necessity for the National Government to again strongly recommend JE vaccination and prevent JE infections in Japan's population.

Acknowledgments

This work was supported in part by a grant-in-aid from Research on Emerging and Re-emerging Infectious Diseases, the Ministry of Health, Labour and Welfare of Japan (H20-Shinkou-ippan-003).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.vaccine.2010.01.008.

References

- [1] Gubler DJ, Kuno G, Flaviviruses ML. In: Knipe DM, Howley PM, editors. *Fields virology*. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1153–252.
- [2] Halstead SB, Jacobson J. Japanese encephalitis. *Adv Virus Res* 2003;61:103–38.
- [3] Lindenbach BD, Thiel H-J, Rice CM. *Flaviviridae: the viruses and their replication*. In: Knipe DM, Howley PM, editors. *Fields virology*. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1052–101.
- [4] Oya A, Kurane I. Japanese encephalitis for a reference to international travelers. *J Travel Med* 2007;14:259–68.
- [5] Arai S, Matsunaga Y, Takasaki T, Tanaka-Taya K, Taniguchi K, Okabe N, et al. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. *Jpn J Infect Dis* 2008;61:333–8.
- [6] Igarashi A. Japanese encephalitis: virus, infection, and control. In: Kurstak E, editor. *Control of virus diseases*. 2nd ed. New York: Marcel Dekker; 1992. p. 309–42.
- [7] Fukuda H, Umehara F, Kawahigashi N, Suehara M, Osame M. Acute disseminated myelitis after Japanese B encephalitis vaccination. *J Neurol Sci* 1997;148:113–5.
- [8] Takahashi H, Pool V, Tsai I TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. *Vaccine* 2000;18:2963–9.
- [9] Okabe N. Background of recent JE vaccine issues. *Virus* 2005;55:303–6 [in Japanese with English abstract].
- [10] Kurane I. Evaluation of mouse brain-derived, inactivated Japanese encephalitis vaccine. *Virus* 2005;55:307–12 [in Japanese with English abstract].
- [11] National Institute of Infectious Diseases, Infectious Disease Surveillance Center. National epidemiological surveillance of vaccine-preventable diseases, 2007. Age distribution of Japanese encephalitis vaccination history in Japan; 2007. <http://idsc.nih.gov/jp/yosoku/JE/Vac-JE2007-e.html> (accessed 18 December 2009).
- [12] National Institute of Infectious Diseases, Infectious Disease Surveillance Center. National epidemiological surveillance of vaccine-preventable diseases, 2007. Seroprevalence of Japanese encephalitis NT antibody in Japan; 2007. <http://idsc.nih.gov/jp/yosoku/JE/Serum-JE2007-e.html> (accessed 18 December 2009).
- [13] Southam CM. Serological studies of encephalitis in Japan. II. Inapparent infections by Japanese B encephalitis virus. *J Inf Dis* 1956;99:155–62.
- [14] Southam CM. Serological studies of encephalitis in Japan. III. Epidemic encephalitis other than Japanese B encephalitis in Tokyo. *J Infect Dis* 1956;99:170–3.
- [15] Halstead SB, Grosz CR. Subclinical Japanese encephalitis. I. Infection of Americans with limited residence in Korea. *Am J Hyg* 1962;75:190–201.
- [16] Grossman RA, Edelman R, Willhight M, Pantuwatana S, Udomsakdi S. Study of Japanese encephalitis virus in Chiangmai Valley, Thailand. III. Human seroepidemiology and in apparent infections. *Am J Epidemiol* 1973;98:133–49.
- [17] Konishi E, Suzuki T. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. *Vaccine* 2002;21:98–107.
- [18] Konishi E, Shoda M, Yamamoto S, Arai S, Tanaka-Taya K, Okabe N. Natural infection with Japanese encephalitis virus among inhabitants of Japan: a nationwide survey of antibodies against nonstructural 1 protein. *Vaccine* 2006;24:3054–6.
- [19] Matsunaga T, Shoda M, Konishi E. Japanese encephalitis remains common in Japan. *Pediatric Inf Dis J* 2008;27:769–70.
- [20] National Institute of Infectious Diseases, Department of Virology 1 and Infectious Disease Surveillance Center. Japanese encephalitis. In: Annual report 2006, National epidemiological surveillance of vaccine-preventable diseases. Tokyo, Tuberculosis and Infectious Diseases Control Division, Health Service Bureau, Ministry of Health Labour and Welfare, Government of Japan, and Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan; 2008. p. 79–103 [in Japanese].
- [21] National Institute of Infectious Diseases, Infectious Disease Surveillance Center. National epidemiological surveillance of vaccine preventable diseases. Infection of swine with Japanese encephalitis virus; 2008 (April–October) <http://idsc.nih.gov/jp/yosoku/JE/JEmap2008-E.html> (accessed 18 December 2009).
- [22] Konishi E, Kitai Y. Detection by ELISA of antibodies to Japanese encephalitis virus nonstructural 1 protein induced in subclinically infected humans. *Vaccine* 2009;27:7053–8.
- [23] Konishi E, Shoda M, Ajiro N, Kondo T. Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infections in vaccinated horses. *J Clin Microbiol* 2004;42:5087–93.
- [24] Oliveira NM, Broom AK, Mackenzie JS, Smith DW, Lindsay MD, Kay BH, et al. Epitope-blocking enzyme-linked immunosorbent assay for detection of antibodies to Ross River virus in vertebrate sera. *Clin Vaccine Immunol* 2006;13:814–7.
- [25] Oya A, Okuno T. *Experimental virology, the Researcher's Association of the National Institute of Health*. 2nd ed. Tokyo, Japan: Maruzen Press Ltd.; 1975. p. 124–62 [in Japanese].
- [26] Clarke DH, Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. *Am J Trop Med Hyg* 1958;7:561–73.
- [27] Instruction for use of Freeze-dried Japanese Encephalitis Vaccine (Cell Culture derived) JEBIK V. The Research Foundation for Microbial Diseases of Osaka University, 2009.
- [28] National Institute of Infectious Diseases, Department of Virology 1 and Infectious Disease Surveillance Center. Japanese encephalitis. In: Annual report 2004, National epidemiological surveillance of vaccine-preventable diseases. Tokyo, Tuberculosis and Infectious Diseases Control Division, Health Service Bureau, Ministry of Health Labour and Welfare, Government of Japan, and Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan; 2006. p. 92–113 [in Japanese].
- [29] National Institute of Infectious Diseases. Japanese encephalitis. <http://www.nih.gov/jp/vir1/NVL/JEVMeeting.htm> (accessed 18 December 2009).
- [30] Nerome R, Tajima S, Takasaki T, Yoshida T, Kotaki A, Lim CK, et al. Molecular epidemiological analyses of Japanese encephalitis virus isolates from swine in Japan from 2002 to 2004. *J Gen Virol* 2007;88:2762–8.
- [31] Takegami T, Ishak H, Miyamoto C, Shirai Y, Kamimura K. Isolation and molecular comparison of Japanese encephalitis virus in Ishikawa, Japan. *Jpn J Infect Dis* 2000;53:178–9.
- [32] Kuwayama M, Ito M, Takao S, Shimazu Y, Fukuda S, Miyazaki K, et al. Japanese encephalitis virus in meningitis patients, Japan. *Emerg Infect Dis* 2005;11:471–3.
- [33] Nabeshima T, Loan HT, Inoue S, Sumiyoshi M, Haruta Y, Nga PT. Evidence of frequent introductions of Japanese encephalitis virus from south-east Asia and continental east Asia to Japan. *J Gen Virol* 2009;90:827–32.

Complement-Dependent Cytotoxicity Assay for Differentiating West Nile Virus from Japanese Encephalitis Virus Infections in Horses[∇]

Yoko Kitai,¹ Takashi Kondo,² and Eiji Konishi^{1,3*}

Division of Infectious Diseases, Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan¹; Epizootic Research Center, Equine Research Institute, Japan Racing Association, Tochigi, Japan²; and Division of Vaccinology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan³

Received 3 June 2009/Returned for modification 27 August 2009/Accepted 8 March 2010

A complement-dependent cytotoxicity (CDC) assay was established to measure antibodies to the West Nile virus (WNV) nonstructural protein 1 (NS1) in horses. Sera collected from a WNV-infected horse mediated lysis of WNV NS1-expressing cells in a dose-dependent manner at higher percentages than sera from a Japanese encephalitis virus (JEV)-infected horse. The percentages of specific lysis for sera diluted 1:10 to 1:80 were <19.8% (assay cutoff) for almost all of the 100 JEV-infected or uninfected horses tested, in contrast to 55 to 76% in WNV-infected horses. Experimental infection revealed that horses became anti-WNV NS1 antibody positive 10 days after WNV infection. This study demonstrated the utility of this assay for differentiating WNV from JEV infections in horses.

West Nile virus (WNV) and Japanese encephalitis virus (JEV) are included in the Japanese encephalitis (JE) serological group of the *Flavivirus* genus of the *Flaviviridae* family (4, 13). JEV is distributed mostly in Asia, whereas WNV is spread worldwide, apart from most areas of Asia (3, 14, 17). There is a possibility that WNV may be introduced into Asia including Japan, similar to its introduction and rapid expansion in the Western Hemisphere. Since the clinical features of WNV infection in humans and horses (6, 16) are similar to those caused by JEV (2, 16), the differential diagnosis of WNV from JEV infections is reliant on laboratory tests. The neutralization test provides the highest specificity among currently available serodiagnostic tests (11). However, even with the neutralization test, cross-reactivity among members of the JE serological group can affect a differential diagnosis, making it difficult to differentiate between WNV and JEV infections (11). Experiments using mice (12), pigs (18), and horses (15) have indicated that upon infection with WNV, animals preimmune to JEV by vaccination or infection induce strong anamnestic responses to JEV. Specifically, neutralizing antibody levels against JEV are commonly equivalent to or even higher than those against WNV.

Antibody-mediated complement-dependent cytotoxicity (CDC) is a mechanism whereby complement activation triggered by specific antibody binding to an antigen on a cell surface causes the formation of the C5b-9 membrane attack complex, which can lyse the target cell (1). We have previously shown the usefulness of this mechanism for measuring antibodies to the nonstructural protein 1 (NS1) of JEV in equine sera (7). In the present study, we examined if the CDC assay could be applied for the detection of antibodies to NS1 of

WNV and if this was able to differentiate WNV from JEV infections in horses.

Sera obtained from horses experimentally infected with WNV have been described previously (5). Briefly, two 1-year-old thoroughbred horses (yearlings; horse numbers 1 and 2) were infected subcutaneously with 1×10^7 PFU of the NY99 strain of WNV. Serum collected from horse 1 at 28 days postinfection was used as a positive control in the present CDC assay and the conventional enzyme-linked immunosorbent assay (ELISA). Sera from 100 individual thoroughbred horses born and kept in Japan were used as negative controls for antibodies to WNV NS1, as in our previous study (5). Of the 100 sera, 40 were negative and 60 positive for anti-JEV NS1 antibodies as determined by ELISA (8). The 40 sera that were negative for JEV NS1 antibodies were collected from 20 yearlings vaccinated with inactivated JE vaccine and 20 without vaccination. All 40 of these horses were born and kept in an area of northern Japan where JEV is not endemic. The 60 sera positive for JEV NS1 antibodies were collected from horses aged 3 to 12 years, as used in our earlier survey (9). All animal experiments were conducted according to the Guidelines for Animal Experimentation at the Equine Research Institute.

The CDC assay previously established for measuring JEV NS1 antibodies (7) was modified to detect WNV NS1 antibodies. The antigen used for the present assay was a stably transfected 2G2 cell line that constitutively expresses the NS1 protein of the WNV Eg101 strain (5). Fifty microliters of serum-free minimal essential medium (SF-MEM) containing 5×10^4 2G2 recombinant cells was mixed with an equal volume of heat-inactivated test serum diluted in SF-MEM and incubated on ice for 30 min. This mixture was then mixed with 11 μ l of commercial rabbit complement (Low-Tox-M rabbit complement; Cedarlane, Hornby, Canada) for a final concentration of 10% and incubated at 37°C for 2 h. Following centrifugation, 50 μ l of the supernatant was mixed with 50 μ l of a lactose dehydrogenase (LDH) substrate (Cytotoxicity Detection Kit Plus; Roche, Mannheim, Germany) and incubated at room temperature for 15 min. The resulting color reaction was

* Corresponding author. Mailing address: Department of International Health, Kobe University Graduate School of Health Sciences, 7-10-2, Tomogaoka, Suma-ku, Kobe 654-0142, Japan. Phone and fax: 81-78-796-4594. E-mail: ekon@kobe-u.ac.jp.

[∇] Published ahead of print on 17 March 2010.




FIG. 1. Comparison of dose-dependent antibody responses of the CDC assay and ELISA to detect anti-WNV NS1 antibodies. Sera from horses experimentally infected with WNV (horse number 1 at 28 days after infection; closed circles) or naturally infected with JEV (open circles) were tested for WNV NS1 antibodies by the CDC assay (left panel) and a conventional ELISA (right panel). A conventional ELISA was performed essentially following a method previously described (5) except that 3 ng of WNV NS1 antigen from culture fluid of 2G2 cells per well was used in this study. Serial 2-fold dilutions of sera starting from 1:10 or 1:100 dilutions were used in the CDC assay or conventional ELISA, respectively. Each datum represents an average obtained in two separate experiments (standard deviations are indicated by bars).

read by spectrophotometry at 490 nm. All procedures were performed in duplicate in 96-well microplates. The percentage of specific cell lysis was calculated according to the manufacturer's instructions using the following formula: $100 \times [(A - C)/(B - C)]$, where A represents the absorbance value obtained with test serum (experimental release), B represents the absorbance obtained by lysing all of the target cells with 1% Triton X-100 (maximum release), and C represents the absorbance obtained with target cells incubated in SF-MEM containing rabbit complement at 10% (minimum release). When this calculation provided a negative value, 0.0% was assigned as the result. Test sera with a specific lysis percentage greater than the cutoff value (19.8% of specific lysis) were determined to be positive for WNV NS1 antibodies. For the one-dilution method, the percentages of specific cell lysis obtained in 1:10 to 1:80 dilution series of sera were used as the WNV NS1 antibody level. In the end point method, the WNV NS1 antibody titer was expressed as the highest serum dilution giving greater than 19.8% of specific lysis.

The dose-response curve obtained in the present CDC assay using serum from WNV-infected horses and WNV NS1-expressing cells (Fig. 1, left panel, closed circles) was consistent with previous reports using serum from JEV-infected horses and JEV NS1-expressing cells (7). This provided validation of the CDC assay for measuring WNV NS1 antibodies in horse sera. Percentages of specific lysis were higher than those obtained with serum from JEV-infected horses at most serum dilutions, although two sera showed equivalent WNV NS1 antibody levels in the ELISA (Fig. 1, right panel).

The usefulness of the present CDC assay for differentiating WNV from JEV infections was determined using a total of 100 samples collected from individual thoroughbred horses regarded as free of antibodies to WNV (Fig. 2A). Serum dilutions of 1:10 to 1:80 showed that most of these sera had less than 20% specific lysis, which was lower than the 54.5 to 75.5% levels obtained with the positive control serum (horse 1 at 28




FIG. 2. Distribution of CDC antibody levels/titers in horse sera regarded as negative for WNV NS1 antibodies and sera from a WNV-infected horse. (A) CDC antibody levels obtained by the one-dilution method. Four 2-fold dilutions of sera, 1:10 to 1:80, were used. (B) CDC antibody titers obtained with the end point method. Four groups used for comparison included samples from 20 yearlings without JE vaccination (group I), 20 yearlings with JE vaccination (group II), 60 horses positive for JEV NS1 antibodies (group III), and horse number 1 at 28 days after experimental infection with WNV (group IV). Data of group IV were obtained from five independent experiments. Circles indicate individual data, while ellipses indicate a group of data showing 0.0% specific lysis or an antibody titer of <1:10. The number of individuals contained in the ellipses is given below each ellipse. For groups I to III or IV, open or closed squares with bars indicate averages and standard deviations, respectively. Dotted lines indicate the cutoff value for the one-dilution (19.8%) or end point (1:10) method of the CDC assay.

days after infection) in five separate experiments. We determined that 19.8% was an appropriate cutoff value to differentiate positive from negative samples for antibodies to WNV NS1. This value was calculated by the mean (4.08%) plus 2 times the standard deviation (7.85%) of the percentage of specific lysis obtained at the 1:10 dilution. Under this cutoff, all of the 40 horses without antibodies to JEV NS1 were negative for WNV NS1 antibodies, even in a 1:10 dilution of sera, irrespective of whether these horses were vaccinated. Of the 60 horses with antibodies to JEV NS1, only 5 were positive at a 1:10 dilution and 1 at 1:20; there were no positive sera at 1:40 and 1:80 dilutions. The end point method, which overcomes the limitations of the one-dilution method, which cannot correctly measure high antibody levels (Fig. 2B), indicated that there were antibody titers of <1:10 in 95 of 100 negative samples, in contrast to 1:160 in the positive control. These




FIG. 3. Time courses of WNV NS1 antibodies in two horses experimentally infected with WNV. Sera were tested by the one-dilution method at serum dilutions of 1:10, 1:20, 1:40, and 1:80 and the end point method of the CDC assay. For comparison, data of the blocking ELISA, conventional ELISA to measure WNV NS1 antibodies, and neutralizing test were included from our earlier study (5). Each datum of the CDC assay represents an average obtained in two separate experiments (standard deviations are indicated by bars). Dotted lines indicate the cutoff values for the one-dilution (19.8%) or the end point (1:10) method of the CDC assay. Dashed lines indicate the cutoff value in the blocking ELISA (27.6%). The week zero time point on the abscissa indicates the sample taken immediately before the WNV infection.

results indicated a clear difference between sera from WNV- and JEV-infected horses in the present CDC assay, as well as the reproducibility of this assay.

To further evaluate the usefulness of the CDC assay, we tested sera from two horses experimentally infected with WNV (Fig. 3). For comparison, time courses of antibody levels/titers previously obtained in the conventional ELISA, the blocking ELISA, and neutralization test (5) are included in Fig. 3. With the one-dilution method of the CDC assay, percentages of specific lysis obtained in a 1:10 dilution of serum started increasing on day 10 and then plateaued at approximately 70 to 80% on day 12 for both horses. Even at serum dilutions of 1:20 to 1:80, both horses became positive within 18 days after WNV infection. The time courses obtained by the end point method were essentially consistent with those obtained by the one-dilution method. In the blocking ELISA, the percentage of inhibition started increasing on day 10, identical to the time course shown in the CDC assay. However, seroconversion was detected on days 12 (horse 1) and 14 (horse 2) by the blocking ELISA, which was slightly later than determined by the CDC assay (day 10). The conventional ELISA first detected WNV NS1 antibodies on day 10, consistent with the time point when antibody levels were shown to increase in the CDC assay and blocking ELISA. The neutralization titers, mainly represented by antibodies to the WNV envelope (E) protein, began to increase on day 7 and then plateaued on day 10, earlier than

the increase in WNV NS1 antibodies detected by other methods. These results indicated that the present CDC assay can measure antibodies to WNV NS1 in horses, similar to the blocking ELISA.

In an earlier study using a JEV model (7), we characterized the CDC assay as a method for antibody testing and showed that such an assay can differentiate antigen-specific from non-specific reactions more effectively than ELISA. Specifically, almost all sera from nonimmune animals at a 1:10 dilution showed no nonspecific lysis using MF6 cells expressing JEV NS1 protein. Similarly, none of the 40 sera we regarded as free from WNV NS1 antibodies and also not containing antibodies to JEV NS1 showed specific lysis (0.0%) at a 1:20 dilution using 2G2 cells expressing WNV NS1 protein. Since 28 of the 40 sera showed low-level lysis (0.17 to 7.48%) at a 1:10 dilution, the ability of the CDC assay to differentiate antigen-specific from nonspecific reactions seems, to some extent, to differ according to the cell line.

The ability of the CDC assay to measure virus-specific antibodies more effectively than cross-reactive antibodies in a model of WNV and JEV is supported by a recent report indicating that JEV NS1 antibodies do not mediate CDC of WNV-infected cells, despite their ability to immunoprecipitate WNV NS1 (10). Similar to neutralization test results, functional antibodies detected by the CDC assay seem to be more virus specific than antibodies detected by a binding assay such as the ELISA.

The cutoff point for determining serum samples as positive for WNV NS1 antibodies is important for differentiating WNV from JEV infections in the present CDC assay. When 1:10 dilutions of sera were used, 5 of the 100 WNV NS1 antibody-negative sera showed positive results (Fig. 2). Further dilutions of sera decreased the number of false-positive samples to one at 1:20 and zero at 1:40 and 1:80 dilutions. Thus, the 1:40 or 1:80 dilution used in the one-dilution method with a cutoff for specific lysis of 19.8%, or in the end point method as a borderline dilution, is considered to provide stringent criteria for the CDC assay, with false-positive results unlikely to occur.

In conclusion, the present study showed that the CDC assay can measure WNV NS1 antibodies in horse sera. Thus, this assay would be a useful tool for differentiating WNV from JEV infections in serological diagnoses.

This study was supported in part by grants from the Japan Racing Association, from Research on Emerging and Re-emerging Infectious Diseases, the Ministry of Health, Labor and Welfare of Japan (H20-shinkou-ippan-003), and from the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, the Ministry of Education, Culture, Sports, Science and Technology, Japan.

REFERENCES

- Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober. 1996. Current protocols in immunology. John Wiley & Sons, Inc. New York, NY.
- Endy, T. P., and A. Nisalak. 2002. Japanese encephalitis virus: ecology and epidemiology. *Curr. Top. Microbiol. Immunol.* 267:11–48.
- Gould, E. A., and S. Higgs. 2009. Impact of climate change and other factors on emerging arbovirus diseases. *Trans. R. Soc. Trop. Med. Hyg.* 103:109–121.
- Gubler, D. J., G. Kuno, and L. Markoff. 2007. Flaviviruses, p. 1153–1252. In D. M. Knipe, P. M. Howley (ed.), *Fields virology*, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
- Kitai, Y., M. Shoda, T. Kondo, and E. Konishi. 2007. Epitope-blocking enzyme-linked immunosorbent assay to differentiate West Nile virus from

- Japanese encephalitis virus infections in equine sera. *Clin. Vaccine Immunol.* **14**:1024–1031.
6. Komar, N. 2003. West Nile virus: epidemiology and ecology in North America. *Adv. Virus Res.* **61**:185–234.
 7. Konishi, E., Y. Kitai, and T. Kondo. 2008. Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus. *Clin. Vaccine Immunol.* **15**:88–94.
 8. Konishi, E., M. Shoda, N. Ajiro, and T. Kondo. 2004. Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect sub-clinical infections in vaccinated horses. *J. Clin. Microbiol.* **42**:5087–5093.
 9. Konishi, E., M. Shoda, and T. Kondo. 2004. Prevalence of antibody to Japanese encephalitis virus nonstructural 1 protein among racchorses in Japan: indication of natural infection and need for continuous vaccination. *Vaccine* **22**:1097–1103.
 10. Krishna, V. D., M. Rangappa, and V. Satchidanandam. 2009. Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. *J. Virol.* **83**:4766–4777.
 11. Kuno, G. 2003. Serodiagnosis of flaviviral infections and vaccinations in humans. *Adv. Virus Res.* **61**:3–65.
 12. Lim, C. K., T. Takasaki, A. Kotaki, and I. Kurane. 2008. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. *Virology* **374**:60–70.
 13. Mackenzie, J. S., A. D. Barrett, and V. Deubel. 2002. The Japanese encephalitis serological group of flaviviruses: a brief introduction to the group. *Curr. Top. Microbiol. Immunol.* **267**:1–10.
 14. Petersen, L. R., and E. B. Hayes. 2008. West Nile virus in the Americas. *Med. Clin. North Am.* **92**:1307–1322.
 15. Shirafuji, H., K. Kanehira, T. Kamio, M. Kubo, T. Shibahara, M. Konishi, K. Murakami, Y. Nakamura, T. Yamanaka, T. Kondo, T. Matsumura, M. Muranaka, and Y. Katayama. 2009. Antibody responses induced by experimental West Nile virus infection with or without previous immunization with inactivated Japanese encephalitis vaccine in horses. *J. Vet. Med. Sci.* **71**:969–974.
 16. Solomon, T., and D. W. Vaughn. 2002. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. *Curr. Top. Microbiol. Immunol.* **267**:171–194.
 17. Trevejo, R. T., and M. Eidson. 2008. Zoonosis update: West Nile virus. *J. Am. Vet. Med. Assoc.* **232**:1302–1309.
 18. Williams, D. T., P. W. Daniels, R. A. Lunt, L. F. Wang, K. M. Newberry, and J. S. Mackenzie. 2001. Experimental infections of pigs with Japanese encephalitis virus and closely related Australian flaviviruses. *Am. J. Trop. Med. Hyg.* **65**:379–387.

Short Communication

Antibodies to Bovine Serum Albumin in Human Sera:
Problems and Solutions with Casein-Based ELISA in the
Detection of Natural Japanese Encephalitis Virus Infections

Eiji Konishi^{1,2*}, Yoko Kitai¹, Koichi Nishimura³, and Seiya Harada³

¹Department of International Health, Kobe University Graduate School of Health Sciences, Kobe 654-0142,

²Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe 650-0017; and

³Division of Microbiology, Kumamoto Prefectural Institute of Public Health and
Environmental Science, Kumamoto 869-0425, Japan

(Received March 3, 2010. Accepted June 10, 2010)

SUMMARY: An ELISA system for measuring antibodies to nonstructural protein 1 (NS1) of Japanese encephalitis virus has already been established. This system uses an ELISA diluent containing casein, instead of bovine serum albumin (BSA). During a survey, we found that 21 (21%) of 102 children aged 1–5 years, who had no history of Japanese encephalitis vaccination and were without detectable neutralizing antibodies, showed positive results with this ELISA system. Western blotting analysis showed that sera from 19 (91%) of these 21 subjects had antibodies to BSA, but not NS1. These sera reacted with BSA antigen remaining in immunoaffinity-purified NS1 antigen. One solution to this problem was to reduce the BSA level to $\leq 1\%$ of the NS1 amount. Another was to use a control well sensitized with BSA with the same amount as that contained in the NS1 antigen preparation.

Japanese encephalitis virus (JEV) of the genus *Flavivirus* in the family *Flaviviridae*, is the leading cause of viral encephalitis in Asia (1). While Japanese encephalitis (JE) is vaccine preventable (2), the recommendation for JE vaccination in Japan was suspended in 2005 (3,4). The significance of a vaccination program is a topic that has generated much debate. This is because the current low JE incidence may also be attributable to the decreased number of vector mosquitoes along with the relocation of pig farms further away from residential areas. However, the natural infection rate in humans is a critical factor for evaluating any need for continuous vaccination.

Antibodies to JEV nonstructural protein 1 (NS1) constitute a marker of natural infection among populations vaccinated with an inactivated JE vaccine (5). Although ELISA is a serological method suited for antibody surveys, nonspecific reactions occurring in human sera have hampered the reliable measurement of low-level NS1 antibodies induced in subclinically infected humans. We have found that the nonspecific reactions occurring in a system using an ELISA diluent containing bovine serum albumin (BSA) were minimized when casein-based diluent was used (6).

The ELISA protocol has been described (6). The only characteristic feature compared with those of a conventional ELISA scheme was the ELISA diluent, which was composed of 0.05 M Tris-HCl (pH 8.0) containing 0.2% casein, 0.05% Tween 20, 1 mM EDTA, and

0.15 M NaCl. Briefly, microplates sensitized with purified NS1 antigens at 10 ng/well were incubated serially with test sera and alkaline phosphatase-conjugated goat anti-human IgG. Both were prepared in the ELISA diluent. The NS1 antigen used for sensitization was immunoaffinity-purified from culture fluids of NS1-expressing cells using a monoclonal antibody specific for NS1. Nonsensitized control wells were run in parallel and differences in absorbance from antigen-sensitized wells were regarded as NS1-specific reactions.

During an NS1 antibody survey using sera collected in Kumamoto Prefecture from 2004 to 2008 (7), we noticed that a large population (21%, 21 of 102) of children aged 1–5 years, who had no vaccination history and no detectable neutralizing antibodies, showed positive results in our ELISA for measuring NS1 antibodies. Although NS1 antibodies detected by our ELISA do not necessarily correlate with E antibodies detected by the neutralization test, we could find no specific reasons to explain this high prevalence of NS1 antibodies.

These 21 samples were then analyzed on Western blots. Since the antigen lot used for the ELISA that produced the above results (positive for NS1 antibodies) had run out by the time of the present study, a different lot was used as the antigen for this analysis. Of these, 19 (91%) showed a visible band at the molecular weight equivalent to that of BSA but did not show any bands corresponding to NS1. Three examples are shown in Fig. 1A. To confirm the reaction with BSA, we examined these samples for reactivity against varying amounts of BSA sensitized on an ELISA plate (Fig. 1B). The reaction was found to depend on the amount of BSA. These results indicated that some sera contained antibodies to BSA that may have caused false-positive results in the ELISA measuring NS1 antibodies. BSA antibodies and their effects on serological tests have

*Corresponding author: Mailing address: Department of International Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma, Kobe 654-0142, Japan. Tel & Fax: +81-78-796-4594, E-mail: ekon@kobe-u.ac.jp




Fig. 1. Reaction between BSA antibodies in human sera and BSA antigen contained in a purified NS1 antigen preparation. (A) Western blotting analyses of sera of children with no history of JE vaccination and with no detectable neutralizing antibodies. Analyses were performed essentially as previously described (6). Briefly, an immunoaffinity-purified NS1 antigen was run on standard Laemmli gels under nonreducing conditions and transferred to a polyvinylidene difluoride membrane. The membrane was incubated with test specimens and alkaline phosphatase-conjugated anti-human IgG. Test sera were collected in Kumamoto Prefecture (7): sera #2 (3-year-old female), #3 (4-year-old female), and #4 (5-year-old female) determined as negative (-) for neutralizing antibodies (Neut Ab) and positive (+) for NS1 antibodies (NS1 Ab) in our ELISA. As a reference, gels were silver-stained or blots were reacted with mouse monoclonal JE-6H4 (MAB) or sera from a JE patient and a subclinically infected human (#1). (B) Dose-dependent ELISA reactivities of human sera against varying concentrations of BSA used for sensitization of the plate. Samples were sera #2 (open circle), #3 (closed circle), and #4 (closed triangle). (C) Purification process and NS1 antigen purity. The antigen concentration of immunoaffinity purification was expressed as an average of the first four eluates. The "Second-round affinity" indicates that the eluates obtained from the "First-round affinity" process were repeatedly affinity-purified by the same procedure. "Absorption" indicates that the "First-round affinity" sample was incubated with rabbit anti-BSA coupled to Sepharose 4B beads at 0°C for 2 h. The latter two procedures were performed with a portion of the "First-round affinity" sample; with the antigen amounts obtained adjusted to those obtained after the "First-round affinity" process. (D) Effect of the use of BSA-sensitized wells on NS1 antibody levels. Using sera with (10 samples; closed circles) or without (6 samples; open circles) a band corresponding to BSA on Western blots, NS1 antibody levels obtained using BSA-sensitized wells were compared with the original NS1 antibody levels obtained using nonsensitized wells.

been reported in healthy human sera, particularly from infants, and are probably induced by dietary proteins (8,9).

The above analysis also showed the presence of BSA in this lot of the affinity-purified NS1 preparation. A direct ELISA using horseradish peroxidase-conjugated rabbit anti-BSA (Alpha Diagnostic International, San Antonio, Tex., USA) measured 1.25 ng of BSA in 10 ng of this NS1 antigen lot, corresponding to one plate well. It appeared that the immunoaffinity-purification strategy cannot always eliminate the BSA originally contained in the maintenance medium of NS1-expressing cells at a concentration of 0.075% (750 µg/ml). Therefore, mini-

mizing the amount of BSA remaining in the NS1 antigen preparation appears a solution to the problem occurring in casein-based ELISA. The above dose-response curve (Fig. 1B) showed that the reaction was undetectable in an amount of BSA of ≤ 1 ng/ml (≤ 0.1 ng/well), indicating that the effect of BSA on the present ELISA was minimized at $\leq 1\%$ of the NS1 antigen (10 ng/well).

Attempts to minimize the relative amount of BSA by repeating immunoaffinity purification steps failed: a high BSA:NS1 ratio remained and there was a considerable loss of NS1 antigen (Fig. 1C). The most effective method to reduce the amount of BSA antigen was absorption with rabbit anti-BSA (Alpha Diagnostic Inter-

national) coupled to Sepharose 4B beads (NHS-activated Sepharose 4B Fast Flow; GE Healthcare UK, Buckinghamshire, England). Specifically, the absorption reduced the amount of BSA to $\leq 1\%$ of NS1 without loss of the NS1 antigen (Fig. 1C).

Another way to resolve the issue was the use of an equivalent amount of BSA in a nonsensitized control. Subtraction of the absorbances obtained with nonsensitized control wells from those obtained with antigen-sensitized wells is considered in theory, and is often used to reduce nonspecific reactions occurring in ELISA. Thus, we sensitized wells with BSA with the same amount contained in the purified NS1 antigen preparation (1.25 ng per well) and compared the results with those obtained using truly nonsensitized wells prepared by incubation only with ELISA coating buffer. As shown in Fig. 1D, 10 sera that were positive for BSA antibodies on Western blots turned negative for NS1 antibodies in ELISA when BSA-sensitized wells were used, whereas six NS1-positive sera that were negative for BSA antibodies on Western blots remained positive for NS1 antibodies.

In conclusion, the present study showed that BSA antibodies, which were found in a relatively large population of children, were the cause of false-positive results in our ELISA using casein-based diluent. However, the present study was able to minimize the effect of BSA antibodies by reducing the BSA level to $\leq 1\%$ in the NS1 antigen preparation, and achieved the same by using an equivalent amount of BSA in nonsensitized control wells. Although the use of medium without BSA would be a theoretical solution, some serum samples that were

originally negative became positive when NS1 antigens prepared using serum-free or casein-containing medium were used.

Acknowledgments This work was supported in part by a grant-in-aid through Research on Emerging and Re-emerging Infectious Diseases, the Ministry of Health, Labour and Welfare of Japan (H20-Shinkou-ippan-003).

REFERENCES

1. Gubler, D.J., Kuno, G., and Markoff, L. (2007): Flaviviruses. p. 1153-1252. *In* D. M. Knipe and P.M. Howley (ed.), *Fields Virology*. 5th ed. Lippincott Williams & Wilkins, Philadelphia.
2. Oya, A. and Kurane, I. (2007): Japanese encephalitis for a reference to international travelers. *J. Travel Med.*, 14, 259-268.
3. Okabe, N. (2005): Background of recent JE vaccine issues. *Virus*, 55, 303-306 (in Japanese with English abstract).
4. Kurane, I. (2005): Evaluation of mouse brain-derived, inactivated Japanese encephalitis vaccine. *Virus*, 55, 307-312 (in Japanese with English abstract).
5. Kuno, G. (2003): Serodiagnosis of flaviviral infections and vaccinations in humans. *Adv. Virus Res.*, 61, 3-65.
6. Konishi, E. and Kitai, Y. (2009): Detection by ELISA of antibodies to Japanese encephalitis virus nonstructural 1 protein induced in subclinically infected humans. *Vaccine*, 27, 7053-7058.
7. Konishi, E., Kitai, Y., Tabei, Y., et al. (2010): Natural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program. *Vaccine*, 28, 2664-2670.
8. Hilger, C., Grigioni, F., De Beaufort, C., et al. (2001): Differential binding of IgG and IgA antibodies to antigenic determinants of bovine serum albumin. *Clin. Exp. Immunol.*, 123, 387-394.
9. Pickering, J.W., Larson, M.T., Martins, T.B., et al. (2010): Elimination of false-positive results in a luminex assay for pneumococcal antibodies. *Clin. Vaccine Immunol.*, 17, 185-189.



Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine

Needle-free jet injection of small doses of Japanese encephalitis DNA and inactivated vaccine mixture induces neutralizing antibodies in miniature pigs and protects against fetal death and mummification in pregnant sows

Jun-ichi Imoto^a, Tomohiro Ishikawa^a, Atsushi Yamanaka^b, Misako Konishi^c, Kenji Murakami^c, Tomoyuki Shibahara^d, Masanori Kubo^d, Chang-Kweng Lim^e, Masataka Hamano^e, Tomohiko Takasaki^e, Ichiro Kurane^e, Haruhide Udagawa^f, Yoshihiro Mukuta^f, Eiji Konishi^{a,b,*}

^a Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan

^b Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan

^c Research Team for Viral Diseases, National Institute of Animal Health, Tsukuba, Ibaraki, Japan

^d Swine pathology unit, National Institute of Animal Health, Tsukuba, Ibaraki, Japan

^e Laboratory of Vector Borne Viruses, Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan

^f Medical Systems Division, Shimadzu Corporation, Kyoto, Japan

ARTICLE INFO

Article history:

Received 16 January 2010

Received in revised form 28 August 2010

Accepted 3 September 2010

Available online 17 September 2010

Keywords:

Japanese encephalitis

DNA vaccine

Swine

Needle-free injection

ABSTRACT

Japanese encephalitis (JE) virus causes abortion and stillbirth in swine, and encephalitis in humans and horses. We have previously reported that immunogenicity of a DNA vaccine against JE was synergistically enhanced in mice by co-immunization with a commercial inactivated JE vaccine (JEVAX) under a needle-free injection system. Here, we found that this immunization strategy was also effective in miniature pigs. Because of the synergism, miniature pigs immunized twice with a mixture of 10 µg of DNA and a 1/100 dose of JEVAX developed a high neutralizing antibody titer (1:190 at 90% plaque reduction assay). Even using 1 µg of DNA, 3 of 4 pigs developed neutralizing antibodies. Following challenge, all miniature pigs with detectable neutralizing antibodies were protected against viremia. Pregnant sows inoculated with 10 or 1 µg of DNA mixed with JEVAX (1/100 dose) developed antibody titers of 1:40–1:320. Following challenge, fetal death and mummification were protected against in DNA/JEVAX-immunized sows.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Japanese encephalitis virus (JEV), a member of the genus *Flavivirus* of the family *Flaviviridae*, is a zoonotic pathogen of medical and veterinary importance [1]. It causes encephalitis in humans and horses, and abortion and stillbirth in pigs. The virus is distributed in many areas of Asia and parts of Oceania [2]. Approximately 50,000 human cases and 10,000 deaths are reported every year, mostly in countries that have no mass vaccination program [3]. In Japan, several thousand equine JE cases were reported in one year during large epizootics in the 1930s and 1940s [4]. A survey carried out in 1947 in Hamana district, central Japan, revealed that 40% of pregnant sows had stillbirths in the epidemic season [5]. Even after vaccinations started in 1948, a nationwide survey in 1969 showed that 53% of unvaccinated pregnant sows aborted as a result of JEV infection [6]. Therefore, JEV infections would cause significant eco-

nomic losses to the swine industry in those pig-raising countries in Asia without vaccination programs.

JE is a vaccine-preventable disease. For humans, a formalin-inactivated purified JEV preparation produced from infected mouse brains (JEVAX) has been widely used [7]. Mass vaccination campaigns using JEVAX have successfully controlled JE epidemics in countries such as Japan, Korea and Taiwan. For veterinary use, a formalin-inactivated vaccine derived from porcine kidney cells or chick embryo cells [8], and live-attenuated vaccines derived from porcine kidney cells [9], bovine kidney cells [10], hamster kidney or lung cells [11] or quail cells [12] are used in swine or horses. In Japan, all racehorses are vaccinated every year and no JE cases have been reported since 1986 [13,14]. However, in 2003 one JE case was reported in a horse not used for racing and which was not vaccinated [15]. Also, it has been recommended that breeding sows be vaccinated and only 0–25 JEV-infected sows were reported in Japan every year during the period 1988–2007 [13,16]. The decreases in reported equine and swine JE cases following introduction of vaccines for animal use indicate the efficacies of the various programs.

The major difficulty for pig-raising Asian countries regarding the introduction of a JE vaccine program is the cost of the vaccine

* Corresponding author at: Department of International Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan. Tel.: +81 78 796 4594; fax: +81 78 796 4594.

E-mail address: ekon@kobe-u.ac.jp (E. Konishi).